Saphnelo 300 mg concentrate for solution for infusion clinical trials

ANISE-II; ANIfrolumab treatment for 24 weeks in patients with primary Sjögren’s syndrome – Efficacy and safety assessment in a randomized, double-blind, placebo-controlled phase-IIa proof-of-concept trial

This study is testing a new medicine called Saphnelo for Sjogren's disease. Researchers want to see if it helps reduce symptoms and if it's safe over 24 weeks. Patients will either receive Saphnelo or a dummy medicine.